Literature DB >> 29535142

65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update.

Luis V Syro1, Fabio Rotondo2, Leon D Ortiz3, Kalman Kovacs2.   

Abstract

Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma. Since 2006, it has been used for the treatment of pituitary carcinomas and aggressive pituitary adenomas. Here, we discuss the current indications and results of temozolomide therapy in pituitary tumors, as well as frequently asked questions regarding temozolomide treatment, duration of therapy, dosage, tumor recurrence and resistance.
© 2018 Society for Endocrinology.

Entities:  

Keywords:  chemotherapy; neoplasms; neuroendocrine tumors; pituitary; temozolomide

Mesh：

Substances：

Year:  2018        PMID： 29535142     DOI： 10.1530/ERC-18-0015

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN： 1351-0088            Impact factor:   5.678


  8 in total

Review 1.  Aggressive nonfunctioning pituitary neuroendocrine tumors.

Authors:  Sérgio Portovedo; Leonardo Vieira Neto; Christina Maeda Takiya; Leandro Miranda-Alves; Paula Soares; Denise Pires de Carvalho
Journal:  Brain Tumor Pathol       Date:  2022-06-20       Impact factor: 3.154

2.  Long-Term Use of Temozolomide as Safe and Effective Therapy for an Aggressive Corticotroph Adenoma in a Very Old Patient.

Authors:  Maria Chiara Decaroli; Anna Ansaloni; Maria Laura Monzani; Marco Losa; Elena Zunarelli; Vincenzo Rochira; Bruno Madeo
Journal:  J Endocr Soc       Date:  2021-04-10

Review 3.  Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues.

Authors:  Renato Cozzi; Maria R Ambrosio; Roberto Attanasio; Alessandro Bozzao; Laura De Marinis; Ernesto De Menis; Edoardo Guastamacchia; Andrea Lania; Giovanni Lasio; Francesco Logoluso; Pietro Maffei; Maurizio Poggi; Vincenzo Toscano; Michele Zini; Philippe Chanson; Laurence Katznelson
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2020       Impact factor: 2.895

4.  Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?

Authors:  Ken Ho; Maria Fleseriu; Ursula Kaiser; Roberto Salvatori; Thierry Brue; M Beatriz Lopes; Pamela Kunz; Mark Molitch; Sally A Camper; Mônica Gadelha; Luis V Syro; Edward Laws; Martin Reincke; Hiroshi Nishioka; Ashley Grossman; Ariel Barkan; Felipe Casanueva; John Wass; Adam Mamelak; Laurence Katznelson; Aart J van der Lely; Sally Radovick; Martin Bidlingmaier; Margaret Boguszewski; Jens Bollerslev; Andrew R Hoffman; Nelson Oyesiku; Gerald Raverot; Anat Ben-Shlomo; Rob Fowkes; Ilan Shimon; Hidenori Fukuoka; Alberto M Pereira; Yona Greenman; Anthony P Heaney; Mark Gurnell; Gudmundur Johannsson; Robert Y Osamura; Michael Buchfelder; Maria Chiara Zatelli; Marta Korbonits; Philippe Chanson; Nienke Biermasz; David R Clemmons; Niki Karavitaki; Marcello D Bronstein; Peter Trainer; Shlomo Melmed
Journal:  J Endocr Soc       Date:  2021-02-09

Review 5.  Pituitary carcinoma - case series and review of the literature.

Authors:  Stephanie Du Four; Jorn Van Der Veken; Johnny Duerinck; Elle Vermeulen; Corina E Andreescu; Michael Bruneau; Bart Neyns; Van Velthoven; Brigitte Velkeniers
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-08       Impact factor: 6.055

Review 6.  Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions.

Authors:  Luis V Syro; Fabio Rotondo; Mauricio Camargo; Leon D Ortiz; Carlos A Serna; Kalman Kovacs
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-15       Impact factor: 5.555

7.  Effective long-term temozolomide rechallenge in a macroprolactinoma

Authors:  Benedetta Zampetti; Giorgia Simonetti; Roberto Attanasio; Antonio Silvani; Renato Cozzi
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-09-25

8.  Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes.

Authors:  Liza Das; Ashutosh Rai; Pravin Salunke; Chirag Kamal Ahuja; Ashwani Sood; Bishan Dass Radotra; Ridhi Sood; Márta Korbonits; Pinaki Dutta
Journal:  J Endocr Soc       Date:  2021-12-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.